Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Wednesday, January 31, 2018
A group of industry investors has announced the acquisition of CorePharma, its facilities and equipment in Middlesex, NJ from Impax Laboratories.
read more
CordenPharma announced the signing of an amendment to their existing manufacturing agreement with Moderna, a clinical stage biotechnology company.
read more
CordenPharma announced the signing of an amendment to their existing manufacturing agreement with Moderna to create a new generation of transformative medicines for patients.
read more
CordenPharma and GE Healthcare’s Dharmacon business have entered a collaboration to create an end-to-end solution for oligonucleotide-based drug discovery.
read more
CordenPharma Plankstadt announced the design and installment of a new manufacturing line dedicated to producing Veterinary Drug Products for 500kg scale batch sizes to supply a complex product for application in the veterinary health market.
read more
Thursday, August 29, 2013
International Chemical Investors Group (ICIG) and the Solvay Group have entered into an agreement under which ICIG will acquire Peptisyntha SA, the Brussels, Belgium, based custom manufacturer of peptides for pharmaceutical use. Upon closing of the ...
read more
With an organic capex investment in Two Phases, the strategic expansion provides biotech and pharma customers with a fully-integrated API to Drug Product service offering organized under a new Oligonucleotides Platform.
read more
Thursday, January 12, 2023
CordenPharma is pleased to announce the signing of a multi-year agreement commencing in 2023 for the contract manufacturing of a large-volume peptide at its CordenPharma Colorado facility.
read more
CordenPharma Latina has received news that the US-FDA warning letter previously received has been closed, with a closeout date of August 15, 2017.
read more
Tuesday, December 06, 2022
CordenPharma, a full-service Contract Development Manufacturing Organization (CDMO) of innovative Active Pharmaceutical Ingredients (APIs), Lipid Excipients, and Drug Products, is proud to announce that as of 1 December 2022, it has joined the ...
read more
CordenPharma has announced its largest strategic investment to date with a committed spend of ~€900m over the next 3 years to grow its Peptide technology platform.
read more
Friday, September 15, 2023
CordenPharma announced the inauguration of increased commercial peptide production capacity with newly-upgraded facilities at CordenPharma Colorado, the largest Solid-Phase Peptide Synthesis (SPPS) Manufacturing facility worldwide.
read more
CordenPharma announced a >€1 billion strategic investment in peptide development and manufacturing.
read more
Wednesday, March 06, 2024
CordenPharma has announced the commissioning of new GMP capacities at Frankfurt to manufacture early clinical phase peptide APIs for pharma and biotech customers. The investment, which is still being finalized, will be fully operational in Q2 2024 ...
read more
CordenPharma, a Contract Development and Manufacturing Organization (CDMO), created a new Technology & Science Advisory Board (TSAB) with eight world-class experts from academia and industry, who will provide strategic guidance and scientific ...
read more